Monthly Prescribing Reference

Trial Evaluating At-Home PSVT Treatment With Etripamil Nasal Spray Misses Primary End Point

heart ecg Topline results were announced from the phase 3 NODE-301 trial of etripamil nasal spray (Milestone Pharmaceuticals), a novel short-acting calcium channel blocker, being investigated for the ...
Mena FN

Paroxysmal Supraventricular Tachycardia (PSVT) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...
WGHP

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

As such, Milestone will leverage the approved PSVT indication and the PSVT program data, along with a single pivotal Phase 3 study in patients with AFib-RVR. About Paroxysmal Supraventricular ...
Medscape

NODE-1: Simple Nasal Spray May Short-circuit Acute PSVT

CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data ...
Medscape

More Good News for Self-Administered Nasal Spray in PSVT

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...
Monthly Prescribing Reference

Cardamyst Approved for Self-Treatment of PSVT Episodes

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...
Mena FN

Milestone Receives FDA Approval Of CARDAMYSTTM (Etripamil) As First And Only Self-Administered Nasal Spray For Adults With Paroxysmal Supraventricular Tachycardia (PSVT)

PSVT, also called SVT, is characterized by episodes of abnormally fast heart rate. Most people with PSVT experience multiple sustained episodes that require treatment on an annual basis. Until now, ...
Finanznachrichten

Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...